Rachel Friedman

Has grant

Associate Professor

Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Recent Grants

Grant: Close

MerTK Mediated T Cell Suppression in the Pancreatic Islets During Type 1 Diabetes

Open Date: 2017-01-04

Close Date: 2021-12-31

Grant: Close

Antigen-specific tolerance through TAM receptor delivery

Open Date: 2016-09-01

Close Date: 2018-08-31

Grant: Close

Role of Formins in Islet Infiltration in Type 1 Diabetes

Open Date: 2015-07-01

Close Date: 2018-06-30

Grant: Close

Role of Islet-Infiltrating Lymphocytes in Obesity

Open Date: 2015-06-24

Close Date: 2018-05-31

Grant: Close

Antigen receptor signaling in the islets of obese individuals

Open Date: 2014-09-01

Close Date: 2015-08-01

Articles (3)

The EphB4-ephrinB2 signaling axis has been heavily implicated in metastasis across numerous cancer types. Our emerging understanding of the dichotomous roles that EphB4 and ephrinB2 play in head and neck squamous cell carcinoma (HNSCC) poses a significant challenge to rational drug design. We find that EphB4 knockdown in cancer cells enhances metastasis in preclinical HNSCC models by augmenting immunosuppressive cells like T regulatory cells (Tregs) within the tumor microenvironment. EphB4 inhibition in cancer cells also amplifies their ability to metastasize through increased expression of genes associated with epithelial mesenchymal transition and hallmark pathways of metastasis. In contrast, vascular ephrinB2 knockout coupled with radiation therapy (RT) enhances anti-tumor immunity, reduces Treg accumulation into the tumor, and decreases metastasis. Notably, targeting the EphB4-ephrinB2 signaling axis with the engineered EphB4 ligands EFNB2-Fc-His and Fc-TNYL-RAW-GS reduces local tumor growth and distant metastasis in a preclinical model of HNSCC. Our data suggest that targeted inhibition of vascular ephrinB2 while avoiding inhibition of EphB4 in cancer cells could be a promising strategy to mitigate HNSCC metastasis.

Year:

2024

Year:

2021

Year:

2021

Collaborators (7)

Erika Rodriguez

Senior Clinical Professional

-

UNITED STATES
View details

Douglas Osborne

senior scientist

Washington University in St. Louis

UNITED STATES
View details

Anthony J. Saviola

University of Colorado Anschutz Medical Campus

UNITED STATES
View details

Elena Pasquale

Professor

Sanford Burnham Prebys Medical Discovery Institute

UNITED STATES
View details

Sana D. Karam

Professor and Department Chair

Washington University in St. Louis

UNITED STATES
View details

Mohit Kapoor

University Health Network

CANADA
View details

Jordan Jacobelli

Associate Professor

University of Colorado School of Medicine

UNITED STATES
View details